Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate

Archives of Ophthalmology

Volumn 129, Issue 5, 2011, Pages 667-668

  Birnbaum, Andrea D ^a   Jiang, Yi ^b   Tessler, Howard H ^a   Goldstein, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLUPREDNATE; PREDNISOLONE ACETATE;

ADOLESCENT; ADULT; ANTERIOR CHAMBER INFLAMMATION; ARTICLE; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE INFLAMMATION; HUMAN; INTRAOCULAR PRESSURE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TONOMETRY; TREATMENT DURATION; TREATMENT WITHDRAWAL; UVEITIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; FLUPREDNISOLONE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MIDDLE AGED; OCULAR HYPERTENSION; UVEITIS; YOUNG ADULT;

EID: 79955784647     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.82     Document Type: Article

References (8)

1. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS; Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35(1):26-34.
2. Mochizuki M, Ohno S, Usui M, Masuda K, Sekiya T, Ogawa T; DFBA Study Group. A phase III, open-label, clinical study of difluprednate ophthalmic emulsion (DFBA), 0.05% in the treatment of severe refractory anterior uveitis [e-abstract 3905]. Invest Ophthalmol Vis Sci. 2007;48:B809.
3. Ohji M, Tano Y, Hida T, Sekiya T, Ogawa T; DFBA Study Group. Efficacy and safety results of a phase III study of difluprednate ophthalmic emulsion (DFBA), 0.5% in postoperative inflammation [e-abstract 3903]. Invest Ophthalmol Vis Sci. 2007;48:B807.
4. Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26(5):475-483.
5. Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-390.
6. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516. (Pubitemid 41224845)
7. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye, I: the demonstration of three levels of response. Invest Ophthalmol. 1965;4:187-197.
8. Dunne JA, Travers JP. Double-blind clinical trial of topical steroids in anterior uveitis. Br J Ophthalmol. 1979;63(11):762-767. (Pubitemid 10236319)